Author: malaysiang

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications. Main disease areas include cardio-renal-metabolic (CRM) diseases, mental health, pulmonary fibrosis, systemic sclerosis, and chronic liver disease, some of them in the late-stage development of the company’s strong innovation pipeline. The expansion will create 110 additional jobs and boost medicine exports from Greece, particularly of Jardiance®, a medication used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease, to the US market.

Greek Prime Minister Kyriakos Mitsotakis attended the groundbreaking ceremony at the Koropi site today, alongside the Minister of State, the Minister of Health and the Minister of Development. He said: “I am delighted to once again visit this plant which, as we have heard, produces some of the most innovative antidiabetic medicines, and to see the excellent organization as well as the high level of expertise and professionalism. I am also very pleased with the progress that the company has made; with the 700 skilled employees whose number will increase by more than 100 when this investment is completed; and, of course, with this important shift towards innovation. I want to thank the company for its continuous trust in Greece. But first and foremost, the company trusts you, the employees, not just the government or the wider environment. All together you constitute a team, building a better tomorrow, a structure with very strong foundations and that is what we are celebrating here today. You showcase the great importance we associate with the creation of value through innovation. It is a strategic goal that we as a state also embrace: to make our country a reference point for the pharmaceutical industry.”

Putting innovative production technologies in place to support successful Research & Development (R&D) is a key investment driver at Boehringer. In 2022, the company’s global expenditure in Human Pharma R&D amounted to 4.6 billion EUR. 25% of Human Pharma net sales are reinvested to advance science and cutting-edge research to find new therapies and treatments for patients who are waiting for new solutions in areas of high unmet patient needs. More than half of its 53,000 workforce and over 60% of R&D budgets are invested in Europe.

“We have been present in Greece since 1996, and have gradually expanded our operations in the country,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors at Boehringer Ingelheim. “This expansion investment will bring some of our most innovative therapies to an increasing number of patients globally.”

Boehringer started the production facility in Koropi in 1975. In 2020, the company announced multi-year investments to expand the site and its production capacity. The Koropi plant is the only industrial facility of a multinational pharmaceutical company in Greece producing innovative medicines.

Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com.

Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Click here to see the press release on the company website

GlobeNewswire Distribution ID 1000908358

REGENETEN Patch 2024

First published randomized controlled trial for market-leading implant demonstrates impressive outcomes for rotator cuff tears               

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces standout results for its REGENETEN Bioinductive Implant from a recently completed randomized controlled trial (RCT). Published online in Arthroscopy in December, the report concluded that at one-year, medium and large full-thickness rotator cuff tears repaired and augmented with the REGENETEN Bioinductive Implant had better tendon healing compared to the standard of care,¹ as evidenced by:

• A significantly lower re-tear rate (8.3 vs 25.8%; p=0.01)
• A three times lower risk of re-tear (RR=0.32; 95% CI:0.13–0.83)
• No difference in the number of serious or minor complications

The blinded, multi-centre RCT compared the healing rate of full-thickness rotator cuff tears repaired with and without augmentation with the REGENETEN Bioinductive Implant. In total, 124 patients with reparable medium and large (1–4cm) full-thickness posterosuperior rotator cuff tears were randomized to receive either an arthroscopic transosseous equivalent double-row rotator cuff repair or the same repair augmented with the REGENETEN Bioinductive Implant.

Dr. Miguel Ruiz Ibán, Head of the Shoulder and Elbow Unit at Hospital Universitario Ramón y Cajal in Madrid, Spain, and Principal Investigator for the study commented on the results, “Rotator cuff repair is traditionally associated with re-tear rates in excess of 20%, presenting a challenge for surgeons and patients alike. This RCT demonstrates that the REGENETEN Bioinductive Implant substantially and significantly reduced this risk. With no increase in complications seen in our study, these findings support the use of the implant to reduce re-tear rates in the population studied.”

With more than 100,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for more than 1 million² people having surgery for a rotator cuff tear each year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of rotator cuff tear progression.^1,3-8

^{Smith+Nephew’s REGENETEN Bioinductive Implant}

“Smith+Nephew is committed to proving the value of our technology through support for clinical evidence generation,” said Christie Van Geffen, SVP Sports Medicine Global Marketing at Smith+Nephew. “We are pleased and excited by the opportunity presented by this evidence to drive adoption of, and access to, the REGENETEN Bioinductive Implant. Our goal is to help surgeons improve the care of many more patients with rotator cuff injuries.”

The REGENETEN Bioinductive Implant is part of Smith+Nephew’s comprehensive Advanced Healing Solutions portfolio – redefining biological healing in rotator cuff repair.

To learn more about the REGENETEN Bioinductive Implant, please click here.

Media Enquiries

David Snyder
Smith+Nephew
+1 978-749-1440
david.snyder@smith-nephew.com

References

1. Ruiz Ibán MA, Navlet MG, Marco SM, et al.  Augmentation of a transosseous equivalent repair in posterosuperior non-acute rotator cuff tears with a bioinductive collagen implant decreases the re-tear rate at one year. A randomised controlled trial. Arthroscopy. Published online 12/27/2023.
2. iData Research. Rotator cuff repair and reconstruction market size, share and trends analysis (2023). Available at: https://idataresearch.com/product/rotator-cuff-repair-reconstruction-market-size-share-and-trends-analysis-global-2023-2029-medsuite-includes-grafts-allografts-xenograft-synthetic-and-1-more/#. Accessed December 19, 2023.
3. Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles, Ligaments Tendons J. 2016;6(1):16-25.
4. Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251.
5. Van Kampen C, Arnoczky S, Parks P, et al. Tissue-engineered augmentation of a rotator cuff tendon using a reconstituted collagen scaffold: a histological evaluation in sheep. Muscles Ligaments Tendons J. 2013;3(3):229-235.
6. Arnoczky SP, Bishai SK, Schofield B, et al. Histologic Evaluation of Biopsy Specimens Obtained After Rotator Cuff Repair Augmented With a Highly Porous Collagen Implant. Arthroscopy. 2017;33(2):278-283
7. Bokor DJ, Sonnabend DH, Deady L, et al. Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments Tendons J. 2019;9(3):338-347.
8. McElvany MD, McGoldrick E, Gee AO, Neradilek MB, Matsen FA, 3rd. Rotator cuff repair: published evidence on factors associated with repair integrity and clinical outcome. Am J Sports Med. 2015;43(2):491-500.

About Smith+Nephew
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 19,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of Covid, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of Covid; economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers (including, without limitation, as a result of Covid); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of Covid); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F,  which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

Smith+Nephew’s REGENETEN Bioinductive Implant

Attachment

• REGENETEN Patch 2024

GlobeNewswire Distribution ID 1000908200

Argentina’s Central Securities Depository (CSD) has successfully launched its new technology platform

Rapidly accelerated launch timetable secures the platform’s ability to meet significant increase in volumes

BUENOS AIRES, Argentina and NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) — Caja de Valores, Argentina’s Central Securities Depository (CSD), today announced it has launched a new technology platform using Nasdaq’s CSD technology. The platform significantly enhances Caja de Valores’ ability to meet immediate operational and performance needs, future proof the business, and position it to capture new growth opportunities.

The launch is the culmination of a multi-year, major change program, which began with Caja de Valores recognizing the potential benefits of modernizing its legacy infrastructure to support the continued growth and institutionalization of Argentina’s capital markets.

In line with many countries around the world, Argentina’s capital market has been subject to periods of substantial increases in volumes which has placed additional strain on the sector’s technology infrastructure. Growth in the market had resulted in Caja de Valores’ technology platform effectively operating at full capacity, necessitating a rapid acceleration of the launch timetable. The core platform went live in September 2023, with more asset classes and additional functionality incorporated ahead of its formal launch in January 2024.

The new platform significantly enhances the resilience, capacity, and speed of the CSD, capable of processing more than 1,000 settlements per second, more than 300 times faster than the previous system. Its scalable architecture will ensure the platform is able to continue serving the Argentine market as it continues to grow.

The company has experienced daily average transactions of 700k, with peaks of 865k. This represents an increase of 49% of the monthly average compared to the period prior to the launch of the new system, due to higher business volumes generated by the Buenos Aires Stock Exchange (BYMA), the owner of Caja de Valores.

Gonzalo Pascual Merlo, CEO of BYMA, said: “We are proud to take this historic step for the custody of the Argentine capital market, which is the result of great teamwork within BYMA and Nasdaq. As an organization, we are committed to the development of the Argentine economy and the growth of the country. For this reason, we constantly invest in world-class technology to offer the infrastructure required to make that happen and help transform investment into prosperity and growth.”

He added: “Like many countries around the world, Argentina’s capital market has been subject to periods of substantial increases in transaction volumes, which has put pressure on its own technological infrastructure. At BYMA we have prepared for this scenario with a new custody system which responds to the needs of our market.”

Magnus Haglind, SVP and Head of Marketplace Technology at Nasdaq, said: “CSDs play a vital role at the heart of the capital markets ecosystem and are increasingly demanding agile infrastructure to respond to incoming regulations, adapt to changing market conditions, and capitalize on emerging growth opportunities. The development of global CSD infrastructure is vital to keep pace with the rapidly changing investment landscape. With much of the post-trade industry running on legacy technology, we welcome the opportunity to partner with Caja de Valores and support the ongoing development of Argentina’s capital market.”

The technology offers standardized protocols to seamlessly connect to both third party and in-house trading and clearing solutions and will benefit from regular upgrades to ensure it remains at the forefront of international standards and best practice. It will significantly reduce the time-to-market for new asset classes, event types and services, and incorporates bespoke connections for existing services. Non-standard instruments – an Argentinian specific asset class – continues to be served on the old system, with Caja de Valores planning to migrate these instruments onto the new platform during the first quarter of 2024.

Nasdaq’s Marketplace Technology business serves as one of the world’s largest market infrastructure technology providers, providing multi-asset solutions to more than 130 marketplaces, CCPs, CSDs and regulators in over 50 countries. It offers reliable and scalable technology across the trade lifecycle, helping organizations to drive efficiency, transparency, and liquidity with unparalleled resiliency.

About Caja de Valores

Caja de Valores is the only entity authorized in Argentina to act as a central depository of marketable securities. It is part of BYMA´S Group, Bolsas y Mercados Argentinos. Caja de Valores offers capital market participants collective deposit, custody, registration, settlement and payment of debts services, as complementary services to those already offered by BYMA as a Stock Exchange, Clearinghouse and Issuer. https://cajadevalores.com.ar/

About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

Caja de Valores Media Contact:
Bernarda Eckell – Comunicación BYMA
comunicacion@byma.com.ar

Nasdaq Media Contact:
Andrew Hughes
+44 (0)7443 100896
Andrew.Hughes@nasdaq.com

-NDAQG-

GlobeNewswire Distribution ID 9016118